IKS03
B-cell malignancies
ClinicalActive
Key Facts
About Iksuda Therapeutics
Iksuda Therapeutics is a clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs) with a mission to design the optimal ADC for specific cancer targets rather than being technology-led. The company has built a pipeline featuring both clinical-stage assets targeting known antigens like CD19 and HER2, and a next-wave pipeline utilizing its proprietary ProAlk payload platform. With a world-class R&D team and a flexible technology model, Iksuda aims to become a partner of choice in the ADC space while advancing therapies for cancers with high unmet need.
View full company profileTherapeutic Areas
Other B-cell malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| CAR-T Program (Hematological) | XellSmart | Phase 1 |
| BAFFR Allo CAR-NK Cells | PeproMene Bio | Pre-clinical |
| TNB-486 | Ancora Bio | Phase 1 |
| docirbrutinib (AS-1763) | Carna Biosciences | Phase 1b |
| Abivertinib | Sorrento Therapeutics | Phase 1/2 |
| Kymriah® (tisagenlecleucel) | Novartis | Approved |
| KITE-363 | Gilead Sciences | Phase 1/2 |
| HSK29116 | Haisco Pharmaceutical Group | Phase I/II |
| TG-1701 | TG Therapeutics | Phase 1 |
| TG-1801 | TG Therapeutics | Phase 1 |
| REC-3565 | Recursion Pharmaceuticals | Phase 1 |
| Plamotamab (XmAb®13676) | Xencor | Phase 2 |